Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

Summary

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.

Timeline

Start

2025-08-28

Primary completion

2028-09

Completion

2029-09

Drugs

Indications